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history of depression and clinically signiﬁcant fatigue.
Methods: Adults with Z2 claims with depression
diagnosis codes identiﬁed from the HealthCore Inte-
grated Research Database were invited to participate in
this study linking survey data with retrospective claims
data (12-mo presurvey and postsurvey periods). Patient
surveys included measures for depression (Quick
Inventory of Depressive Symptomatology), fatigue
(Fatigue Associated with Depression Questionnaire),
anxiety (7-item Generalized Anxiety Disorder scale),
sleep difﬁculty (Athens Insomnia Scale), and pain
(Brief Pain Inventory). After adjusting for demo-
graphic and clinical characteristics using propensity
scores, postsurvey costs were compared between
patients with and without fatigue using nonparametric
bootstrapping methods. Results: Of the 1982 patients
who had completed the survey and had complete claims274 www.psychosomaticsjournal.orgPatients with fatigue reported signiﬁcantly higher
scores, indicating greater severity, on measures of
depression, pain, sleep difﬁculty, and anxiety (all
po 0.05).These patients also had higher levels of overall
medication use and were more likely to have lower
measures of socioeconomic status than patients without
signiﬁcant levels of fatigue (all po 0.05). Mean annual
total costs were greater for patients with fatigue than
those without fatigue ($14,462 vs $9971, respectively,
po 0.001). These cost differences remained statistically
signiﬁcant after adjusting for clinical and demographic
differences. Conclusions: Clinically signiﬁcant fatigue
appears to add to the economic burden of depression. This
reinforces the need for aggressive treatment of all
symptoms and further examination of the variability of
this relationship as patients approach remission.
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Understanding the role of unresolved fatigue in patients
with depression may offer insights into improving efﬁ-
ciencies in health care. Depression is one of the most
common and costly illnesses in the United States, with a
lifetime prevalence rate of 16% in the adult population1,2
and costing approximately $83.1 billion annually (in
2000).3 It is aheterogeneousdisorder involvingdisruptions
of mood, appetite, sleep difﬁculty, motor activity, and
cognition.4 Themagnitude of effect from these symptoms
varies depending on the individual.4 Increasingly, fatiguehas been recognized as one of the most bothersome and
most prevalent symptoms of depression.5–7Psychosomatics 56:3, May/June 2015
Robinson et al.Fatigue is a ubiquitous symptom that is experi-
enced across a wide range of physical and psychiatric
illnesses. Fatigue is difﬁcult to distinguish from other
illnesses, including depression. Fatigue and depression
share a common underlying neurobiology,8 yet they
are also considered to have some distinct pathways or
biochemical differences.9,10 Patients may experience
fatigue as a symptom of depression or another illness,
as prodromal to a depressive episode, or as a
treatment-emergent adverse event.7,11,12
Patients who experience some response to depres-
sive symptoms report that fatigue is one of the more
persistent symptoms of depression.11,13 For example,
64.6% of patients with initial fatigue who responded to
treatment for depression in the Sequenced Treatment
Alternatives to Relieve Depression study continued to
experience fatigue at the end of the study.12 Fatigue
has also been associated with a lower probability of
achieving remission.12,14,15 Fatigue in patients with
depression has also been found to be associated with
poorer functional outcomes.5,16 In a study of 573
patients who initiated treatment for depression, low
energy or tiredness was the depressive symptom most
strongly associated with poor work outcomes, includ-
ing absenteeism, work productivity, and social
functioning.16
Therefore, it may be that unresolved fatigue in
patients with depression is associated with increased
medical costs; however, to our knowledge, this has
not been previously studied. The objective of the
current study was to assess the association of fati-
gue with annual unadjusted and adjusted total costs
for all-causes and mental health–related health
care use.
METHODS
Study Design
The comorbidities and symptoms of depression
study used a retrospective/prospective ﬁxed-cohort
repeated measures design, including initial and
6-month patient surveys linked to 24 months of
administrative claims data (12 mo before the survey
[presurvey period] and 12 mo after the survey [post-
survey period]) from the HealthCore Integra-
ted Research Database. The database contains
geographically diverse claims data from 14 commer-
cial health plans in the United States. HealthPsychosomatics 56:3, May/June 2015plans included health maintenance organizations,
point of service, and preferred provider organi-
zation plans.Study Sample
The study sample was targeted to include 3000
survey respondents. As reported in Figure 1, the study
sample originated from a patient list generated from
administrative claims in the HealthCore Integrated
Research Database that identiﬁed all potential par-
ticipants. Patient eligibility criteria included age
between 18 and 64 years, being a currently active
health plan member, being continuously enrolled in
his or her health plan for Z12 months with both
medical and pharmacy beneﬁts, and having
Z2 distinct medical claims with an International
Classiﬁcation of Diseases, 9th Revision, Clinical
Modiﬁcation code for major depressive disorder
(296.2x, 296.3x, or 300.4x) in the most recent 12
months (June 1, 2009 to May 31, 2010). Patients were
excluded if they had at least 1medical claim for bipolar
disorder (296.0x, 296.1x or 296.4x-296.9x) or schizo-
phrenia (295.xx) in the study period. A central institu-
tional review board approved the study.
Eligible patients were mailed letters in waves
between January 1, 2011, and February 9, 2011, until
target enrollment was met. The letters described the
study and invited patients to participate. Up to
6 attempts were made to contact patients before
considering them unavailable to participate. Con-
tacted patients who gave verbal informed consent
over the telephone were screened for further eligibility
and could complete the survey via telephone or the
Internet. Patients preferring to complete the survey via
the Internet were given 2 weeks from initial contact to
complete the survey. Once the targeted sample of 3000
was reached, no more patients were contacted.
The survey took approximately 30 minutes to
complete, and patients were compensated $35 for their
time. Patients who completed the survey were invited
to participate in an add-on survey consisting of addi-
tional health status instruments and a 6-month follow-
up survey (a 12-mo follow-up survey was also planned
but not conducted). For the purposes of the current
objectives, only the initial survey data are reported.
Survey data were linked to 24months of claims data to
address the study objectives. Approximately 35% of
respondents did not meet the criteria as havingwww.psychosomaticsjournal.org 275
FIGURE 1. Study Patient Sample and Claims Attrition.
Costs and Characteristics of Unresolved Fatigue in Depressioncomplete postperiod claims information and were
excluded from this analysis. When comparing
responses between respondents and nonrespondents,
no major differences were found (data not shown).Measures
Survey Measures
Survey data captured the patient's demographic and
socioeconomic status measures and functioning
(12-item General Health Questionnaire).17 Cohorts
were deﬁned as either patients with fatigue or patients
without fatigue based on the experience subscale of the
Fatigue Associated with Depression (FAsD) Ques-
tionnaire (subscale score Z3.2). The FAsD contains276 www.psychosomaticsjournal.org13 itemswith response values from 1–5. Item responses
are summed and averaged to produce a total scale and
subscales for fatigue, that is, experience and
impact.18,19 Currently, a cut point on the FAsD
indicating signiﬁcant levels of severity has not been
published. Therefore, the cut point for comorbidities
and symptoms of depression study was chosen before
conducting the analysis based on internal consistency
with other fatigue measures and data in clinical
populations (data not shown).
Other patient-reported outcome measures asses-
sed symptoms or conditions of interest as continuous
severitymeasures (higher scores equal greater severity)
and as dichotomous cut points of clinical signiﬁcance
(with/without). Validated cut points were based on
the literature. When more than 1 cut point wasPsychosomatics 56:3, May/June 2015
Robinson et al.documented (as for level of pain and anxiety), the
broader deﬁnition was applied. Measures included the
following:1)PsyDepression: Quick Inventory of Depressive Symp-
tomatology—Self-Report, 16-item version20 (QIDS-
SR) (range: 0–27, cut pointZ6).2) Anxiety: 7-item Generalized Anxiety Disorder
scale21 (range: 0–21, cut point Z8).3) Sleep difﬁculty: Athens Insomnia Scale22 (range:
0–24, cut point Z6).4) Pain: Brief Pain Inventory23 (range: 1–10, cut point
pain on average within the past 24 h Z4).5) Heavy drinking: Item from the Alcohol Consump-
tion Scale24 using a cut point ofZ5 drinks for men
and Z4 drinks for women in a single day or the
presence of presurvey periodmedical claims involv-
ing International Classiﬁcation of Diseases, 9th
Revision diagnosis codes of 303.xx or 305.0x.Administrative Claims Measures
Demographic characteristics, diagnoses, treatment
patterns, health care resource utilization, and costs
were determined from patient eligibility data and
medical and pharmacy claims. Clinical conditions
were identiﬁed using International Classiﬁcation of
Diseases, 9th Revision, Clinical Modiﬁcation diag-
nosis codes on medical claims (Appendix A). Comor-
bidity severity wasmeasured using the Quan-Charlson
index.25 Variables were constructed for the presurvey
and postsurvey periods.
Provider specialty was determined from the most
recent depression diagnosis claim during the presurvey
period. Provider specialty was categorized into pri-
mary care physicians (family or general practitioner,
internal medicine physician, or obstetrician/gynecol-
ogist), psychiatrists, others, and missing/unknown. If
provider specialty was missing, the prescriber identi-
ﬁed from the most recent presurvey antidepressant
pharmacy claim was used.
Treatment patterns included the number of unique
medication classes, antidepressant types, and combina-
tion therapy of antidepressants with second-generation
antipsychotics. Antidepressant use was categorized as
none (no prescription within 183 d presurvey), new
course (prescription within 90 d presurvey but none
between 91 and 183 d presurvey), and ongoing (pre-
scription ﬁlled within 90 d presurvey and Z1chosomatics 56:3, May/June 2015prescription within 91 and 183 d presurvey). Length
of therapy was deﬁned as the sum of days' supply with
overlapping periods counted once, thus capping length
of therapy at 365 days. The medication possession ratio
was deﬁned as the proportion of length of therapy
relative to the 12-month period of interest. Patients with
a medication possession ratio greater than 80% were
categorized as adherent.26
Postsurvey costs (inﬂation-adjusted to 2012) were
computed by summing the expenses incurred by health
plans and patients for inpatient hospitalizations,
emergency department visits, physician ofﬁce visits,
other outpatient visits (e.g., hospital outpatient and
laboratory visits), and pharmacy claims. Mental
health–relatedmedical and pharmacy costs were those
involving International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation codes for psychiatric
conditions or pharmacy claims for psychiatric medi-
cations or both.Statistical Methods
Data were summarized by fatigue cohort status,
including presurvey and postsurvey period measures
from administrative claims of key diagnoses related to
depression, such as double depression, diabetes melli-
tus, cardiovascular disease, and obesity; health care
resource use; and the survey measures. Cohort com-
parisons were made using the chi-square or the Fisher
tests for categorical variables, and 2-sample t-tests for
continuous variables, with signiﬁcance at α ¼ 0.05 for
a 2-sided test.
Unadjusted mean total health care costs were
compared by fatigue cohort using nonparametric
bootstrapping methods, with 95% 2-sided CIs and
p values computed using the bias-corrected and accel-
erated bootstrap to adjust for both bias and skewness in
the bootstrap distribution.27 The prespeciﬁed primary
analysis was a comparison of adjusted mean total
health care costs between the fatigue cohorts. The
analysis between cohorts was calculated by adjusting
for differences in background characteristics and
health status using propensity score bin-boot-
strapping.28 Propensity scores were computed using
logistic regression models, with the fatigue cohort
assignment (with or without fatigue) as the dependent
measure. All measures identiﬁed from the presurvey
period claims and surveys were considered for inclu-
sion as independent covariates based on their potentialwww.psychosomaticsjournal.org 277
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disruptionwas the onlymeasure omitted because it was
deemed too closely related to fatigue to make the
analyses informative. The following variables were
included:278Demographics: sex, age, ethnicity/race, education
status, employment status, marital status, geo-
graphic region of the patient’s residence, family
income, and insurance plan type. Clinical survey characteristics: level of QIDS-SR
(score of 0–5 vs others), presence of anxiety,
presence of pain, and excessive drinking. Presurvey claims information: physician specialty;
Quan-Charlson index; medication possession ratio;
proxy for new course of antidepressant treatment;
claims for second-generation antipsychotic pre-
scriptions; diagnoses of double depression, diabetes
mellitus, cardiovascular disease, and obesity.
Five bins were deﬁned by grouping patients with
similar propensity scores using the propensity score
distribution quintiles.When fewer than 2 patients were
available for any group within a bin, the entire bin was
excluded from subsequent analyses.
The balance between the cohorts achieved using
the propensity score stratiﬁcation was assessed before
conducting the outcome analysis using ordinary least
squares regression analysis for continuous measures
and logistic regression for categorical measures. The
balance assessment demonstrated that the propensity
stratiﬁcation produced balance for most, but not every
covariate. Generalized linear models (using a log link
and gamma distribution) were developed to “double
adjust” for the remaining imbalanced covariates
within each bin,29 and the resulting predicted costs
were used in place of the raw follow-up costs in the
subsequent bootstrap process. The mean difference
between the cohorts was obtained by determining the
average mean difference between the cohorts from the
10,000 bootstrap samples. To help control for multi-
plicity, a single primary analysis was prespeciﬁed.
However, p values from all other analyses are reported
without multiplicity adjustment and should be inter-
preted accordingly.
Sensitivity analyses were conducted to examine
the robustness of the results based on varying
deﬁnitions of depression and fatigue. Because the
study was designed to survey a general population ofwww.psychosomaticsjournal.orgthose with prior major depressive disorder diagnoses,
analyses were repeated using subpopulations of
patients with (1) mild or greater depression severity
(QIDS-SR Z6) and (2) moderate or greater depres-
sion severity (QIDS-SR Z11). Cut points for the
FAsDhave not been published. Therefore, additional
generalized linear model analysis was conducted
using continuous measures from the FAsD subscales
of experience and impact, as well as the FAsD total
scale.
RESULTS
Patient Characteristics
Clinically signiﬁcant fatigue, as deﬁned by the
FAsD experience scale, was present in 32.9%
(n ¼ 653) of patients. Patients were mainly white,
female, and approximately 46 years of age (Table 1).
Compared with the cohort without fatigue, the fatigue
cohort tended to have indicators of lower socioeco-
nomic status in terms of education level and working
status (Table 1). Patients with fatigue vs those without
reported greater mean severity of depression, pain,
sleep difﬁculty, and anxiety (Table 2), as well as other
measures of fatigue. Patients with fatigue also had
lower quality of life and higher prevalence of comor-
bidities in the 12-month presurvey and postsurvey
periods (Table 2).
During the postsurvey follow-up period, the over-
all number of medications used annually, as well as
each medication category assessed, was higher in
patients with fatigue vs those without fatigue
(Table 3). A higher percentage of patients with fatigue
had postsurvey claims for combination use of anti-
depressants with second-generation antipsychotics
(13.6% vs 8.1%, po 0.0001). However, no signiﬁcant
differences were found between cohorts in antidepres-
sant length of therapy (255.8 95.6 vs 252.1 98.7 d,
p ¼ 0.4803) or rate of adherence to antidepressants
over the 12-month follow-up period (50.0% vs 48.0%,
p ¼ 0.4644).
Unadjusted percentages of health care resource
utilization (all-cause) were generally higher in patients
with fatigue than those without during the postsurvey
period for inpatient hospitalizations, emergency
department visits, physician ofﬁce visits, and out-
patient visits. Mental health–related resource utiliza-
tion in the 12-month postsurvey period followedPsychosomatics 56:3, May/June 2015
TABLE 1. Demographic and Clinical Characteristics of the Fatigue Cohorts
Characteristic With fatigue (n ¼ 653) Without fatigue (N ¼ 1329) p Value*
Female, n (%) 522 (79.9) 1010 (76.0) 0.0490
Age (y), mean  SD 46.9  11.0 46.4  11.9 0.3065
Geographic region, n (%)
0.0048
Northeast 95 (14.6) 216 (16.3)
South 183 (28.0) 278 (20.9)
Midwest 182 (27.9) 376 (28.3)
West 188 (28.8) 438 (33.0)
Unknown 5 (0.8) 21 (1.6)
White race, n (%) 596 (91.3) 1210 (91.1) 0.8684
Marital status, n (%) 0.0405
Married/signiﬁcant other 397 (60.8) 742 (55.8)
Single, separated, divorced, or widowed 253 (38.7) 585 (44.0)
Others 3 (0.5) 2 (0.2)
Educational status, n (%) o0.0001
High school or less 152 (23.3) 200 (15.1)
College 387 (59.3) 793 (59.7)
Graduate 113 (17.3) 335 (25.2)
Other 1 (0.2) 1 (0.1)
Employment status, n (%) o0.0001
Employed full time 282 (43.2) 637 (47.9)
Employed part time or self 114 (17.5) 292 (22.0)
Homemaker 76 (11.6) 145 (10.9)
Student 12 (1.8) 43 (3.2)
Disabled, retired, or unemployed 169 (25.9) 212 (16.0)
SD ¼ standard deviation.
n The chi-square or the Fisher tests were used to determine any statistical difference across categorical variables; t-tests were used for
continuous variables.
Robinson et al.similar trends, with patients with fatigue vs those
without incurring more inpatient hospitalizations,
emergency department visits, physician ofﬁce visits,
and other outpatient visits (Table 3).Cost Comparisons
Annual total health care costs for patients with and
without signiﬁcant fatigue are presented in Figure 2.
Unadjusted postsurvey costs were signiﬁcantly greater
in patients with fatigue vs those without fatigue. After
propensity score adjustment, cohorts were generally
well balanced on the predetermined set of covariates,
except for QIDS-SR, primary care physicians spe-
cialty, and regional differences. Therefore, a general-
ized linear model double adjustment was conducted to
address these remaining imbalances. After these
adjustments, the fatigue cohort continued to have
signiﬁcantly higher all-cause total costs. Although
point estimates for mental health–related total costsPsychosomatics 56:3, May/June 2015were higher for patients with vs those without fatigue,
the difference was not statistically signiﬁcant.Sensitivity Analyses
All-cause total annual health care cost comparisons
for the 12-month postsurvey period were examined in
subsets of patients with depression severity greater or
equal to mild depression (QIDS-SR score, Z6) and
moderate depression (QIDS-SR score,Z11) to deter-
mine the robustness of the ﬁndings. In the subset of
patients with at least mild current depression
(n ¼ 1364), mean adjusted health care costs for
patients with fatigue were higher than those without
fatigue ($12,272  $827 vs $11,099  $642, cost
difference of $1173, 95% CI: $941 to $3099), but the
difference was not signiﬁcant. Likewise, in the subset
of patients with at least moderate current depression
(n ¼ 682), adjusted health care costs for patients with
fatigue were also higher than those without fatigue
($14,199  $1129 vs $13,478  $1370, cost differencewww.psychosomaticsjournal.org 279
TABLE 2. Clinical Measures for the Fatigue Cohorts
With fatigue (n ¼ 653) Without fatigue (n ¼ 1329) p Value‡‡
Provider specialty, n (%) 0.0004
Primary care physician* 176 (27.0) 302 (22.7)
Psychiatrist 248 (38.0) 470 (35.4)
Nonphysician 173 (26.5) 406 (30.6)
Others 14 (2.1) 11 (0.8)
Missing/unknown 42 (6.4) 140 (10.5)
Quan-Charlson index, mean  SD 0.7  1.4 0.5  1.0 o0.0001
Presence of postperiod diagnoses from claims
Double depression 60 (9.2) 59 (4.4) o0.0001
Diabetes mellitus 106 (16.2) 118 (8.9) o0.0001
Fatigue/sleep-related conditions† 283 (43.3) 376 (28.3) o0.0001
Cardiovascular disease 38 (5.8) 48 (3.6) 0.0266
Obesity 88 (13.5) 89 (6.7) o0.0001
Anxiety (GAD-7)‡
Clinically relevant presence, n (%) 446 (68.3) 358 (26.9) o0.0001
Severity, mean  SD 10.6  5.4 5.5  4.6 o0.0001
Alcohol consumption§
Clinically relevant level of heavy drinking, n (%) 47 (7.2) 95 (7.2) 0.9681
Severity, mean  SD 9.5  2.4 9.4  2.3 0.6061
Pain (BPI)║
Clinically relevant presence, n (%) 373 (57.1) 342 (25.7) o0.0001
Severity, mean  SD 3.8  2.6 2.0  2.2 o0.0001
Sleep difﬁculty (AIS)¶
Clinically relevant presence, n (%) 580 (88.8%) 639 (48.1%) o0.0001
Severity, mean  SD 10.7  4.5 5.7  3.8 o0.0001
Depression (QIDS-SR), n (%)
No depression 31 (5.0) 521 (40.5) o0.0001
Mild 179 (28.5) 503 (39.1)
Moderate 259 (41.2) 223 (17.3)
Severe 127 (20.2) 38 (3.0)
Very severe 32 (5.1) 3 (0.2)
Severity, mean  SD 12.6  4.5 7.1  4.0 o0.0001
Fatigue (FAsD), mean  SD
Experience subscale# 4.0  0.5 2.3  0.6 o0.0001
Impact subscale** 3.3  0.9 2.0  0.8 o0.0001
Total score†† 3.6  0.6 2.1  0.6 o0.0001
AIS¼Athens Insomnia Scale; BPI¼Brief Pain Inventory; FAsD¼ subscale of theFatigueAssociatedwithDepression;GAD-7¼ 7-item
Generalized Anxiety Disorder; ICD-9-CM ¼ International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation; QIDS-SR ¼
Quick Inventory of Depressive Symptomatology—Self-Report, 16-item version; SD ¼ standard deviation.
n Includes family/general practice, internal medicine and obstetrics/gynecology.
† Fatigue/sleep-related conditions: CFS, general fatigue, anemia, insomnia, hypersomnia, and other sleep disturbances.
‡ GAD-7 cut point of Z8 (range: 0–21).
§ Alcohol consumption scale: cut point ofZ5 (if male) orZ4 (if female) drinks per day at least twice a week, or presence of presurvey
period ICD-9-CM diagnostic claims of 303.xx or 305.0x.
║ BPI: cut point of Z4 (range: 1–10).
¶ Sleep difﬁculty: AIS cut point of Z6 (range: 0–24).
# FAsD experience subscale items with a cut point of 3.2 (range: 1–5).
nn FAsD impact subscale items (range: 1–5).
†† FAsD experience þ impact subscale items (range: 1–5).
‡‡ The chi-square or the Fisher tests were used to determine any statistical difference across categorical variables; t-tests were used for
continuous variables.
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TABLE 3. Health Care Use Over 12 Months of Follow-up for Fatigue Cohorts
Health care utilization With fatigue (n ¼ 653) Without fatigue (n ¼ 1329) p Value
All cause
Any inpatient hospitalizations, n (%) 82 (12.6) 134 (10.1) 0.0966
Any emergency department visits, n (%) 149 (22.8) 197 (14.8) o0.0001
Any physician ofﬁce visits, n (%) 651 (99.7) 1305 (98.2) 0.0058
Any other outpatient visits, n (%)* 616 (94.3) 1221 (91.9) 0.0480
Mental health related
Any inpatient hospitalizations, n (%) 48 (7.4) 62 (4.7) 0.0141
Any emergency department visits, n (%) 46 (7.0) 59 (4.4) 0.0149
Any physician ofﬁce visits, n (%) 551 (84.4) 1020 (76.8) o0.0001
Any other outpatient visits, n (%)* 242 (37.1) 354 (26.6) o0.0001
Pharmaceuticals, n (%)
Antidepressants 544 (83.3) 970 (73.0) o0.0001
Second-generation antipsychotics† 99 (15.2) 125 (9.4) 0.0001
Benzodiazapines 261 (40.0) 360 (27.1) o0.0001
Mood stabilizers‡ 13 (2.0) 11 (0.8) 0.0261
Hypnotics 169 (25.9) 205 (15.4) o0.0001
Anxiolytics 290 (44.4) 409 (30.8) o0.0001
Stimulants 105 (16.1) 140 (10.5) 0.0004
Migraine medications 51 (7.8) 67 (5.1) 0.0143
Analgesics opiates 300 (46.0) 439 (33.0) o0.0001
Analgesic (nonnarcotic) 28 (4.3) 22 (1.7) 0.0004
Analgesic anti-inﬂammatory medications 178 (27.3) 300 (22.6) 0.0219
Steroids 143 (21.9) 242 (18.2) 0.0510
Muscle relaxants 132 (20.2) 167 (12.6) o0.0001
Pain management (based on CPT codes) 77 (11.8) 77 (5.8) o0.0001
Anticonvulsants§ 170 (26.0) 185 (13.9) o0.0001
Antidiabetes medications║ 74 (11.3) 85 (6.4) 0.0001
Gastrointestinal-related medications¶ 76 (11.6) 92 (6.9) 0.0004
Cardiovascular medications# 199 (30.5) 316 (23.8) 0.0014
Endocrine medications** 221 (33.8) 321 (24.2) o0.0001
Insomnia-speciﬁc hypnotics†† 177 (27.1) 220 (16.6) o0.0001
Total number of unique medications, mean  SD 10.6  6.4 7.6  5.0 o0.0001
CPT ¼ Current Procedural Terminology; SD ¼ standard deviation.
n Other outpatients visits included all outpatient visits (except for physician ofﬁce visits), such as hospital outpatient visits and laboratory
visits.
† Second-generation antipsychotics: paliperidone, ziprasidone, quetiapine, risperidone, olanzapine, lurasidone, iloperidone, asenapine
maleate, aripirazole, and clozapine.
‡ Mood stabilizers: carbamazepine, lithium, valproic acid and divalproex sodium, and lamotrigine.
§ Anticonvulsants: gabitril, diazapam, phenytoin, pregabalin, gabapentin, dilantin topamax, and miscellaneous anticonvulsants.
║ Antidiabetic medications: antihyperlipidemia and other antidiabetics.
¶ Gastrointestinal related: laxatives, antidiarrheals, antacids, digestive aids, and other gastrointestinal agents.
# Cardiovascular: antihypertensive, antiarrhythmics, antianginal agents, calcium channel blocking agents,miscellaneous cardiovascular
medications, and corticotropin.
nn Endocrine: thyroid agent, endrocine metabolic regulators, and hormones (noncontraception).
†† Insomnia-speciﬁc hypnotics: temazepam, ﬂurazepam, mephobarbital, quazepam, secobarbital sodium, triazolam, chloral hydrate,
estazolam, eszopiclone, ramelteon, butabarbital, zolpidem, and zaleplon.
Robinson et al.of $721, 95% CI: $3539 to $3148), but again the
difference was not signiﬁcant.
In the full cohort, additional measures of fatigue
were also explored using continuous measures of the
FAsD assessments. In each case, patients with fatigue
accrued signiﬁcantly greater costs. For the experiencePsychosomatics 56:3, May/June 2015subscale score, a 1-unit increase in fatiguewas found to
signiﬁcantly increase a patient's all-cause and mental
health–related costs by 13.6% (95% CI: 6.5–21.2,
p ¼ 0.0001) and 10% (95% CI: 1.6–19.1, p ¼
0.0186), respectively. For the FAsD impact subscale
score, a 1-unit increase in this score was found towww.psychosomaticsjournal.org 281
FIGURE 2. Annual Unadjusted and Adjusted* Postsurvey Total Health Care Costs by Fatigue Cohorts. *CostsWere Adjusted Using Propensity
Score Stratiﬁcation by Demographic Characteristics, Clinical Survey Characteristics Including Symptom and Comorbid Conditions
SeverityMeasures, and Presurvey Claims Information On Comorbid Conditions and Prior Treatments. Generalized LinearModels
(GLMs) Were Used to “double Adjust” for the Following Covariates: Cohort Indicator, Quick Inventory of Depressive
Symptomatology—Self-Report Severity Level (Mild, Moderate, Severe, or Very Severe), Provider Specialty, and Region.
Costs and Characteristics of Unresolved Fatigue in Depressionsigniﬁcantly increase a patient’s all-cause and mental
health–related costs by 12.4% (95% CI: 5.4–19.8,
p ¼ 0.0003) and 10.2% (95% CI: 2.1–19.0, p ¼
0.0128), respectively. The 1-unit increase in the FAsD
total score was found to signiﬁcantly affect a patient's
all-cause and mental health–related costs by 16.9%
(95% CI: 8.5–25.9, p o 0.0001) and 13.4% (95% CI:
3.5–24.3, p ¼ 0.0071), respectively.
CONCLUSIONS
Patients with clinically signiﬁcant fatigue and a
history of depression incurred higher total health care
costs than did patients without fatigue. Cost differ-
ences remained after applying methods to adjust for
cohort differences with respect to demographic and
clinical characteristics. Cost differences were 10%–
20% higher depending on the measures of cost (total
all-cause or mental health–related) and fatigue that
were used.
The presence of clinical levels of fatigue is also
associated with the greater use of health care resour-
ces, including emergency department visits, physician
ofﬁce and other outpatient visits, and increased
medication use. Notably, a greater proportion of
the cohort with fatigue used each medication cat-
egory that was assessed. This rate was more than282 www.psychosomaticsjournal.orgtwice that of the cohort without fatigue for mood
stabilizers, non-narcotic analgesics, pain manage-
ment therapies, anticonvulsants, antidiabetics, and
gastrointestinal-related medications. Fatigue may be
exacerbated as a result of taking these medications.
Not surprisingly, patients with fatigue also reported
an increased severity of depression, pain, sleep
difﬁculty, and anxiety. These ﬁndings are consistent
with other studies that found fatigue to be associa-
ted with other medical and psychiatric illnesses
and to be both a predictor and a consequence of
depression.30
Although clinicians have long recognized the
importance of fatigue as a symptom of depression,16
until recently, there was a lack of an established valid
and reliable tool for assessing fatigue in patients with
depression.18,19 The FAsD is strongly correlated with
other fatigue measures; however, it was developed
using the input of patients with depression and
validated in a depressed population.19
The robustness of the relationship of fatigue to
cost in patients with varying current depression
severity levels was of particular interest. This study
identiﬁed patients based on prior claims diagnoses of
major depressive disorder; therefore, the duration and
course of depression were variable. In this population
of patients who were previously diagnosed withPsychosomatics 56:3, May/June 2015
Robinson et al.depression, 5% of those with fatigue and 40.5% of
those without fatigue reported no depressive symp-
toms at the time of the survey. This may indicate that
fatigue is a marker for more severe depression or,
consistent with others studies, that fatigue is one of the
last symptoms to resolve in a depressive episode.11
These analyses made several attempts to adjust
patient samples based on the level of current depres-
sion. Propensity scores were unable to equate cohorts
on depression severity in the ﬁrst attempt. A double-
adjustment approach adjusted for the remaining
differences. A third approach included sensitivity
analyses wherein the sample was restricted to only
those with at least clinically signiﬁcant depression
(mild to severe) or to those with moderate to severe
depression. In these subsamples of only patients with
greater depression severity, the directional relation-
ship between the presence of fatigue and higher health
care costs was replicated, but the differences were not
signiﬁcant. It appears that fatigue plays a greater role
when the full spectrum of depression is considered.
This may mean that treatment approaches should
address fatigue as patients progress toward remission,
as this may be where the inﬂuence of fatigue on costs
may be most notably affected. Approaches to manag-
ing symptoms of fatigue include the use of pharmaco-
logic and nonpharmacologic therapies. Clinical care
should include providing patient education, providing
guidance on managing activity and diet, and treating
symptoms.10 Other studies have found that cognitive-
behavior therapy and graded exercise therapy are
effective in treating chronic fatigue syndrome
(CFS).31 Recommended treatments for fatigue include
modaﬁnil, armodaﬁnil, methylphenindate, dexaphet-
amine, and caffeine.10 Medications recommended for
sleep speciﬁcally include some medications used for
treating depression and other conditions that have
sedating side effects, such as tricyclics, cyclobenza-
prine, trazodone, and quetiapine.10 In a study of
patients with cancer-related fatigue and depression,
depression-speciﬁc treatments were not sufﬁcient to
treat symptoms of fatigue.32 In the absence of bio-
markers for fatigue or depression, further understand-
ing of these therapies should be explored.
Several limitations should be considered when
interpreting these ﬁndings. The prospective/retrospec-
tive hybrid study design offers an efﬁcient and effective
method to examine outcomes by augmenting surveyPsychosomatics 56:3, May/June 2015data with claims; however, typical limitations of each
of these methods are present. First, fatigue cohorts are
not formed by randomization and, although methods
based on causal inferences were used to adjust for
cohort differences, not all biases may have been
adjusted for in the analysis.
Second, retrospective claims are collected for the
administrative purposes and assume that all prescrip-
tion medications were taken; they lack information on
drug use through over-the-counter medications or
ofﬁce samples. Additionally, medical diagnostic codes
may be incorrectly used or included as rule-out criteria
for diagnosis purposes. This is especially true with
depression, which is frequently underreported in
claims.33
Finally, survey measures cannot distinguish the
origin of fatigue because it may be an unresolved
symptom of depression or another illness or a
treatment-emergent side effect. It may be difﬁcult to
understand the true effect of fatigue, because it shares
variance with depression and other key constructs of
interest. These ﬁndings demonstrated the unique
effects of fatigue after other related variables were
controlled for in the propensity adjustment.
The presence of fatigue in depression appears to
add to the economic burden of depressive illness,
emphasizing the importance of resolution of all
symptoms for improved outcomes. In particular,
fatigue in patients with a history of depression was
associated with increased current depression, anxiety,
sleep difﬁculties, and pain severity. Drug development
efforts that search for treatments that allow differ-
entiating by patterns of symptom presentation and
response or reducing fatigue experienced with some
medications may be a successful strategy. Until then,
these ﬁndings suggest that a clinical management
strategy based on assessing residual symptoms, such
as fatigue, and treating for their full resolution may be
valuable to optimize the clinical and economic out-
comes for patients.
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APPENDIX A. CODES FOR COMORBID
CONDITIONS
Comorbid condition ICD-9-CM codes
Psychiatric conditions
Depression 296.2x, 296.3x, and 300.4x
Other depressive disorders 296.0x to 296.1x, 296.4x to
296.9x, 298.xx, 309.0x,
309.1x, and 311.xx
Substance use V65.42, 977.9, and 303.xx to
305.xx
Alcohol use or dependence 303.xx and 305.0x
Other substance use
conditions
V65.42, 977.9, and 304.xx
Anxiety 300.xx
Generalized anxiety
disorder
300.02
Posttraumatic stress
disorder
309.81
Other anxiety disorder 300.xx, excluding 300.02
Sexual dysfunction and
erectile dysfunction
799.81, 302.71, and 302.72
Memory loss 780.93
Other psychiatric
conditions
290.xx to 316.xx and V40.x,
excluding the following:
295.0x to 295.9x,
299.0x, 299.9x, 302.6x,
307.59, 309.83, 312.1x,
312.2x, 312.81, 312.9x, 313.
xx, 314.9x, 315.35; 296.xx,
298.xx, 300.xx, 302.71,
302.71, 303.xx to 305.xx,
309.0x, 309.1x, 311.xx, and
309.81
Fatigue
CFS 780.71
General fatigue symptoms 780.70, 780.79, and 300.5x
Anemia 280.xx to 284.xx
Insomnia 780.51, 780.52, 307.41, 307.42,
and 327.0x
Comorbid condition ICD-9-CM codes
Hypersomnia 780.53, 780.54, 307.43, 307.44,
and 327.1x
Other sleep disturbance 327.20 to 327.23, 327.29, 327.3x
to 327.8x, 780.50, 780.55 to
780.59, and 786.03
Pain-related syndromes
Back pain 720.xx, 721.2x to 721.9x, 722.1x
to 722.3x, 722.5x, 722.6x,
722.70, 722.72, 722.73, 722.80,
722.82, 722.83, 722.90, 722.92,
722.93, and 724.xx
Fibromyalgia 729.1x, 780.96, 338.xx, and307.80
Other pain 053.1x, 250.6x, 307.8x, 323.xx,
335.20, 335.34, 336.9x, 337.1x,
337.2x, 338.3x, 339.xx, 340.xx,
341.xx, 346.0x to 346.9x, 350.
xx, 351.xx, 353.xx to 356.xx,
357.2x, 358.xx, 524.6x, 577.1x,
696.xx, 714.xx, 715.xx, 719.xx,
720.xx, 721.0x to 722.4x,
722.71, 722.81, 722.91, 723.1x,
724.4x, 728.0x, 729.0x, 729.2x,
729.5x, 784.0x, 786.5x, 789.xx,
733.99, 733.14, 780.71, 820.8x,
820.9x, 951.4x, 952.xx, 953.4x,
and 955.5x to 955.7x;
Procedure code: 88.81
Other comorbidities
Cardiovascular disease 410.xx to 414.xx, 440.xx, 441.
xx, and 443.9x
Cerebrovascular disease,
prior transient ischemic
attack, and stroke
362.34, 430.xx to 438.xx, and
V12.54
Diabetes mellitus 250.xx
Thyroid disorders 241.xx to 246.xx
Obesity 278.0x, V85.3, and V85.4
Cancer 140.xx to 172.xx, 174.xx to 208.
xx, and 238.6x
ICD-9-CM ¼ International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation.
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